Assessing the in vivo data on low/no-calorie sweeteners and the gut microbiota

Low/no-calorie sweeteners (LNCS) are continually under the spotlight in terms of their safety and benefits; in 2014 a study was published linking LNCS to an enhanced risk of glucose intolerance through modulation of the gut microbiota. In response, an in-depth review of the literature was undertaken to evaluate the major contributors to potential changes in the gut microbiota and their corresponding sequelae, and to determine if consuming LNCS (e.g., acesulfame K, aspartame, cyclamate, neotame, saccharin, sucralose, steviol glycosides) contributes to changes in the microbiome based on the data reported in human and animal studies. A few rodent studies with saccharin have reported changes in the gut microbiome, but primarily at high doses that bear no relevance to human consumption. This and other studies suggesting an effect of LNCS on the gut microbiota were found to show no evidence of an actual adverse effect on human health. The sum of the data provides clear evidence that changes in the diet unrelated to LNCS consumption are likely the major determinants of change in gut microbiota numbers and phyla, confirming the viewpoint supported by all the major international food safety and health regulatory authorities that LNCS are safe at currently approved levels

Cross-sectional study of the provision of interventional oncology services in the UK

Objective: To map out the current provision of interventional oncology (IO) services in the UK. Design: Cross-sectional multicentre study. Setting: All National Health Service (NHS) trusts in England and Scottish, Welsh and Northern Ireland health boards. Participants: Interventional radiology (IR) departments in all NHS trusts/health boards in the UK. Results: A total of 179 NHS trusts/health boards were contacted. We received a 100% response rate. Only 19 (11%) institutions had an IO lead. 144 trusts (80%) provided IO services or had a formal pathway of referral in place for patients to a recipient trust. 21 trusts (12%) had plans to provide an IO service or formal referral pathway in the next 12 months only. 14 trusts (8%) did not have a pathway of referral and no plans to implement one. 70 trusts (39%) offered supportive and disease-modifying procedures. One trust had a formal referral pathway for supportive procedures. 73 trusts (41%) provided only supportive procedures (diagnostic or therapeutic). Of these, 43 (59%) had a referral pathway for disease-modifying IO procedures, either from a regional cancer network or through IR networks and 30 trusts (41%) did not have a referral pathway for disease-modifying procedures. Conclusion: The provision of IO services in the UK is promising; however, collaborative networks are necessary to ensure disease-modifying IO procedures are made accessible to all patients and to facilitate larger registry data for research with commissioning of new services

The anti-proliferative Effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage

The mammalian lignan, enterolactone, has been shown to reduce the proliferation of the earlier stages of prostate cancer at physiological concentrations in vitro. However, efficacy in the later stages of the disease occurs at concentrations difficult to achieve through dietary modification. We have therefore investigated what concentration(s) of enterolactone can restrict proliferation in multiple stages of prostate cancer using an in vitro model system of prostate disease. We determined that enterolactone at 20 μM significantly restricted the proliferation of mid and late stage models of prostate disease. These effects were strongly associated with changes in the expression of the DNA licencing genes (GMNN, CDT1, MCM2 and 7), in reduced expression of the miR-106b cluster (miR-106b, miR-93, and miR-25), and in increased expression of the PTEN tumour suppressor gene. We have shown anti-proliferative effects of enterolactone in earlier stages of prostate disease than previously reported and that these effects are mediated, in part, by microRNA-mediated regulation

Consumption of a flavonoid-rich acai meal is associated with acute improvements in vascular function and a reduction in total oxidative status in healthy overweight men

Background: Acai (Euterpe oleracea) is a polyphenol-rich fruit marketed as beneficial for health. Experimental data showing improvements in health markers arising from acai consumption in humans is limited. Objective: The objective of the present study was to investigate the effect of acai consumption on acute changes in vascular function and on other disease risk markers, including postprandial plasma insulin, glucose, and oxidative stress. Design: Twenty-three healthy male volunteers, aged 30–65 y and with a body mass index (in kg/m2) of 25–30, completed a randomized,controlled, high-fat challenge, double-blind, crossover, acute dietary intervention trial. The volunteers consumed either an acai-based smoothie (AS) or a macronutrient-matched control smoothie (PS) together with a high-fat breakfast meal challenge. The primary endpoint was the assessment of endothelial function in the brachial artery by flow-mediated dilatation (FMD). Results: The acute consumption of an AS containing 694 mg total phenolics improved vascular function, with postprandial increases in FMD from baseline of 1.4% at 2 h compared with 0.4% after consumption of the PS (P = 0.001) and increases at 6 h of 0.8% for the AS compared with 20.3% for the PS (P , 0.001). There was also a significantly lower incremental area under the curve (iAUC)for total peroxide oxidative status after acai consumption relative to the control. No significant changes were observed in blood pressure,heart rate, or postprandial glucose response. However, the first postprandial insulin peak (after breakfast) and the iAUC for insulin were elevated for the AS relative to the PS. Conclusions: In this acute study in overweight men, acai consumption was associated with improvements in vascular function, which may lower the risk of a cardiovascular event. Future intervention studies, perhaps with a chronic design, in wider populations and with other biomarkers of disease risk are needed to fully elucidate the benefits of acai to health

1976 Long term rotation trials

Long term rotation trials - W56H, 66M29, 67C13, 67N4, 68E5, 68SG5, 69GE20, 73SG16, Soil fertility - grain lupins - 75TS23

1975 Soil fertility - grain lupins - long term rotation trials

Soil Fertility - Grain Lupins 75A4, 75BA6, 75E4, 75GE9, 75JE9, 75MT6, 75N028, 75WH9. Long Term. Rotation Trials W56H, 66M29, 67Cl3, 67N4, 68E5, 68SG5, 69GE20, 73SG16. Soil Fertility - Grain Lupins Use of the stage 4 lupin variety trials to assess the effect of a year of sweet grain lupins on a following cereal crop was continued. The 1974 variety trials contained a number of lupin varieties randomised with two standard wheat varieties. Also at two times of planting. Eight trials were selected: 74GE26 at Morawa, 74BA7 at Badgingarra, 74WH8 at Wongan Hills, 74N08 at Bolgart, 74A8 at Beverley, 74MT8 at Mount Barker, 74JE9 at Gairdner River, 74E8 at Gibson. The 1974 plots in these trials were sown to Gamenya wheat in 1975 (except for 74MT8, Swan oats used to prevent take-all complication). - 75GE9, 75A4, 75BA6, 75E4, 75GE9, 75JE9, 75MT6, 75N028, 75WH9

Metabolic targets of watercress and PEITC in MCF-7 and MCF-10A cells explain differential sensitisation responses to ionising radiation

Watercress is a rich source of phytochemicals with anticancer potential, including phenethyl isothiocyanate (PEITC). We examined the potential for watercress extracts and PEITC to increase the DNA damage caused by ionising radiation (IR) in breast cancer cells and to be protective against radiation-induced collateral damage in healthy breast cells. The metabolic events that mediate such responses were explored using metabolic profiling. H nuclear magnetic resonance spectroscopy-based metabolic profiling was coupled with DNA damage-related assays (cell cycle, Comet assay, viability assays) to profile the comparative effects of watercress and PEITC in MCF-7 breast cancer cells and MCF-10A non-tumorigenic breast cells with and without exposure to IR. Both the watercress extract and PEITC-modulated biosynthetic pathways of lipid and protein synthesis and resulted in changes in cellular bioenergetics. Disruptions to the redox balance occurred with both treatments in the two cell lines, characterised by shifts in the abundance of glutathione. PEITC enhanced the sensitivity of the breast cancer cells to IR increasing the effectiveness of the cancer-killing process. In contrast, watercress-protected non-tumorigenic breast cells from radiation-induced damage. These effects were driven by changes in the cellular content of the antioxidant glutathione following exposure to PEITC and other phytochemicals in watercress. These findings support the potential prophylactic impact of watercress during radiotherapy. Extracted compounds from watercress and PEITC differentially modulate cellular metabolism collectively enhancing the therapeutic outcomes of radiotherapy

1973 Long term rotation trials

The results shown are the yield of grain harvested from crops grown after various lengths of pasture ley. Experiments - W56H, 66M29, 67BA6, 68E5, 68SG5, 69GE20

Long term rotation trials - Annual summary of results 1975

Long term rotation trials: Results are the yield of grain harvested from crops grown after various lengths of pasture ley. W56H, 66M29, 67C13, 67N4, 68SG5

Long Term Rotation Trials

The object of these trials is to attempt to determine the best rotation for each area or at least give some guidelines for recommendations as to the optimum rotation. Also to determine the effect of various pasture phases on the performance of the following crops and the number of crops required to utilise any accrued benefit from the pasture. In addition the trials on the Salmon Gums Research Station (68SG5) will attempt to compare cereal rotations on both volunteer and barrel medic pastures. It is also hoped to be able to get some estimate of grazing production from barrel medic and volunteer pastures. The trial being run by the Geraldton District Office at Northampton (68GE8) will determine the best rotation for soil badly infected with cereal eelworm. Also find the effect of various lengths of pasture and fallow on the level of eelworm in the soil. The eelworm work is being carried out by Miss Goss of Plant Pathology